The COLOMATE Platform: An Indispensable Initiative Promoting True Precision Oncology Prioritized for Patients With Cancer—From “MAYBE” to “MUST BE”
Takayuki Yoshino, MD, PhD provides perspective on key issues surrounding therapy selection in gastrointestinal cancers.
Clinical Trials in Progress: GOZILA
Nationwide Circulating-Tumor DNA–Guided Basket and Umbrella Clinical Trials for Patients With Advanced Solid Tumors (GOZILA; UMIN000029315)
Comparing GOZILA and COLOMATE: Ongoing Umbrella/Basket Trials Examining Genetic Testing in Gastrointestinal Malignancies
Circulating tumor DNA (ctDNA)-based next- generation sequencing (NGS) assays have advantages over classic tissue-based analyses because of their low invasiveness and availability of repeated sampling. The existence of various companion trials for common alterations that can be potential therapy targets on the 2 platforms can lead to future international collaboration.